Status:
COMPLETED
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
Lead Sponsor:
Federico II University
Conditions:
Exudative Age-related Macular Degeneration
Eligibility:
All Genders
50-80 years
Brief Summary
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coh...
Detailed Description
Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability. The optical coheren...
Eligibility Criteria
Inclusion
- age older than 50 years, diagnosis of exudative age-related macular degeneration, treatment-naïve with Bevacizumab for exudative age-related macular degeneration.
Exclusion
- age younger than 50 years, diagnosis of exudative macular degeneration due to other causes, previous treatments before Bevacizumab for exudative age-related macular degeneration.
Key Trial Info
Start Date :
January 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2017
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04138420
Start Date
January 25 2017
End Date
October 30 2017
Last Update
October 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Naples "Federico II"
Naples, Italy, 80100